D.L. Carlson Investment Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
D.L. Carlson Investment Group's XBI Position: Q1 2026 in Review
D.L. Carlson Investment Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 8.6% in Q1 2026, buying an estimated $154K and bringing the position to 15,532 shares worth $1.98M. The position accounts for 0.34% of the portfolio, ranked #74.
D.L. Carlson Investment Group first reported a position in XBI in Q3 2018 and has held it in 23 quarters since. The position peaked at $10.8M in Q4 2020. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- D.L. Carlson Investment Group held 15,532 shares of State Street SPDR S&P Biotech ETF worth $1.98M as of Q1 2026.
- D.L. Carlson Investment Group bought 1,230 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $154K.
- State Street SPDR S&P Biotech ETF made up 0.34% of D.L. Carlson Investment Group's portfolio in Q1 2026, its #74 holding.
- D.L. Carlson Investment Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and has held it in 23 quarters since.
- D.L. Carlson Investment Group's State Street SPDR S&P Biotech ETF position peaked at $10.8M in Q4 2020.
- 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on D.L. Carlson Investment Group's 13F filing for Q1 2026, filed 13 May 2026.